Literature DB >> 15602072

Management of the elderly person after myocardial infarction.

Wilbert S Aronow1.   

Abstract

Elderly persons after myocardial infarction should have their modifiable coronary artery risk factors intensively treated. Hypertension should be treated with beta blockers and angiotensin-converting enzyme inhibitors. The blood pressure should be reduced to <140/85 mmHg and to > or = 130/80 mmHg in persons with diabetes or renal insufficiency. The serum low-density lipoprotein cholesterol should be reduced to <100 mg/dl with statins if necessary. Aspirin or clopidogrel, beta blockers, and angiotensin-converting enzyme inhibitors should be given indefinitely unless contraindications exist to the use of these drugs. Long-acting nitrates are effective antianginal and antiischemic drugs. There are no Class I indications for the use of calcium channel blockers after myocardial infarction. Postinfarction patients should not receive Class I antiarrhythmic drugs, sotalol, or amiodarone. An automatic implantable cardioverter-defibrillator should be implanted in postinfarction patients at very high risk for sudden cardiac death. Hormonal therapy should not be used in postmenopausal women after myocardial infarction. The two indications for coronary revascularization are prolongation of life and relief of unacceptable symptoms despite optimal medical management.

Entities:  

Mesh:

Year:  2004        PMID: 15602072     DOI: 10.1093/gerona/59.11.1173

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  2 in total

1.  Secondary prevention of heart disease with statins: findings are unexpected.

Authors:  Robert Fleetcroft; Nicholas Steel
Journal:  BMJ       Date:  2005-05-21

2.  Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework.

Authors:  Sheena E Ramsay; Richard W Morris; Olia Papacosta; Lucy T Lennon; Mary C Thomas; Peter H Whincup
Journal:  J Public Health (Oxf)       Date:  2005-09-14       Impact factor: 2.341

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.